Argos Therapeutics, Inc. announced the appointment of Philippe Van Holle to the company's board of directors. Most recently senior vice president of human resources for Celgene Corporation, Mr. Van Holle has more than three decades of marketing and sales experience in the pharmaceutical and biotechnology industries. He has been responsible for setting up European commercial operations for companies including Amgen, Genzyme, and Celgene, and has supported new product launches in hematology, infectious disease, and immunology.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -6.22% | +78.50% |
2019 | Argos Therapeutics, Inc. Went Out of Business | CI |
2019 | First Amended Liquidation Plan Approved for Argos Therapeutics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+78.50% | 567K | |
-1.62% | 89.22B | |
+1.32% | 40.49B | |
-15.73% | 32.79B | |
+64.13% | 26.23B | |
-21.28% | 14.52B | |
-8.50% | 13.09B | |
-44.07% | 11.6B | |
-13.06% | 11.5B | |
+4.94% | 8.82B |
- Stock Market
- Equities
- ARGSQ Stock
- News Argos Therapeutics, Inc.
- Argos Therapeutics, Inc. Names Philippe Van Holle to the Board of Directors